Last reviewed · How we verify
Gimeracil and Oteracil Porassium Capsules
Gimeracil and Oteracil Porassium Capsules is a Pyrimidine synthesis inhibitor Small molecule drug developed by Beijing Biohealthcare Biotechnology Co.,Ltd. It is currently in Phase 2 development for Colorectal cancer.
Inhibits dihydroorotate dehydrogenase
Inhibits dihydroorotate dehydrogenase Used for Colorectal cancer.
At a glance
| Generic name | Gimeracil and Oteracil Porassium Capsules |
|---|---|
| Sponsor | Beijing Biohealthcare Biotechnology Co.,Ltd |
| Drug class | Pyrimidine synthesis inhibitor |
| Target | Dihydroorotate dehydrogenase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Gimeracil and oteracil are used in combination with capecitabine to inhibit dihydroorotate dehydrogenase, an enzyme involved in pyrimidine synthesis, thereby inhibiting tumor cell growth.
Approved indications
- Colorectal cancer
Common side effects
- Diarrhea
- Nausea
- Vomiting
Key clinical trials
- Perioperative Therapy for HER2-negative Hepatoid Adenocarcinoma of Stomach (PHASE2)
- Perioperative Treatment of Hepatoid Adenocarcinoma of Stomach (PHASE2)
- Quintuple Method for Treatment of Multiple Refractory Colorectal Liver Metastases (PHASE2)
- Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer (PHASE2)
- Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin on Pancreatic Cancer (PHASE2)
- Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Gastric Cancer (PHASE2)
- Radical Gastrectomy and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Gastric Cancer (PHASE2)
- Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gimeracil and Oteracil Porassium Capsules CI brief — competitive landscape report
- Gimeracil and Oteracil Porassium Capsules updates RSS · CI watch RSS
- Beijing Biohealthcare Biotechnology Co.,Ltd portfolio CI
Frequently asked questions about Gimeracil and Oteracil Porassium Capsules
What is Gimeracil and Oteracil Porassium Capsules?
How does Gimeracil and Oteracil Porassium Capsules work?
What is Gimeracil and Oteracil Porassium Capsules used for?
Who makes Gimeracil and Oteracil Porassium Capsules?
What drug class is Gimeracil and Oteracil Porassium Capsules in?
What development phase is Gimeracil and Oteracil Porassium Capsules in?
What are the side effects of Gimeracil and Oteracil Porassium Capsules?
What does Gimeracil and Oteracil Porassium Capsules target?
Related
- Drug class: All Pyrimidine synthesis inhibitor drugs
- Target: All drugs targeting Dihydroorotate dehydrogenase
- Manufacturer: Beijing Biohealthcare Biotechnology Co.,Ltd — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Colorectal cancer
- Compare: Gimeracil and Oteracil Porassium Capsules vs similar drugs
- Pricing: Gimeracil and Oteracil Porassium Capsules cost, discount & access